true
0001642380
0001642380
2026-02-20
2026-02-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
(Amendment
No. 1)
Current
Report
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 20, 2026
Insight
Molecular Diagnostics Inc.
(Exact
name of Registrant as specified in its charter)
| California |
|
1-37648 |
|
27-1041563 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File No.) |
|
(IRS
Employer
Identification No.) |
2
International Plaza Dr., Suite 510
Nashville,
Tennessee 37217
(Address
of principal executive offices) (Zip code)
(615)
255-8880
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
Registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
stock, no par value |
|
IMDX |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory
Note: On February 20, 2026, Insight Molecular Diagnostics Inc. (“we,” “us,” “our,” the “Company”
or “iMDx”) filed a Current Report on Form 8-K under Item 1.01 announcing that it had entered into a Specimen Collection Agreement
with Quest Diagnostics Incorporated (“Quest Diagnostics”). This information was inadvertently filed under Item 1.01. This
report corrects and amends that filing by moving the disclosure regarding the agreement with Quest Diagnostics under Item 8.01.
Item
8.01. Other Events.
On
February 20, 2026, iMDx announced that it had entered into a Specimen Collection Agreement with Quest Diagnostics for certain specimen
collection-related services related to the Company’s GraftAssureCoreTM test, a blood test designed to measure donor-derived
cell free DNA (dd-cfDNA) using a novel PCR-based measurement platform.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
INSIGHT
MOLECULAR DIAGNOSTICS INC. |
| |
|
|
| Date:
May 13, 2026 |
By: |
/s/
Peter Hong |
| |
Name: |
Peter
Hong |
| |
Title: |
Vice
President, General Counsel |
